Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBP-717
- Development stage
- Preclinical
- Lead developer
- BridgeBio Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
BBP-717 is an investigational, next-generation monoclonal antibody designed to clear existing amyloid deposits in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Developed by BridgeBio Pharma, BBP-717 is engineered as an amyloid 'depleter' with high-affinity binding for misfolded transthyretin (TTR) fibrils and no detectable binding to native TTR tetramers. It is designed to enhance macrophage phagocytosis of amyloid deposits through Fcγ receptor (FcγR) activation. BBP-717 is intended to complement near-complete TTR stabilization therapies, such as BridgeBio's approved stabilizer Attruby (acoramidis). BridgeBio nominated BBP-717 as a development candidate in Q3 2026 and plans to submit an Investigational New Drug (IND) application to the FDA in 2027.
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)TTR (Transthyretin)
Beyond the preview
Go deeper on BBP-717.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBP-717.